• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

依替巴肽诱发血小板减少症的罕见病例。

A rare case of eptifibatide-induced thrombocytopenia.

作者信息

Kamar Khalil, MacDougall Kira, Alsheikh Mira, Parylo Sara, Skaradinskiy Yevgeniy

机构信息

Department of Internal Medicine, Zucker School of Medicine at Hofstra/Northwell at Staten Island University Hospital, New York, NY, USA.

Department of Hematology & Medical Oncology, Zucker School of Medicine at Hofstra/Northwell at Staten Island University Hospital, New York, NY, USA.

出版信息

J Community Hosp Intern Med Perspect. 2021 Mar 23;11(2):269-272. doi: 10.1080/20009666.2021.1871802.

DOI:10.1080/20009666.2021.1871802
PMID:33889336
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8043518/
Abstract

Eptifibatide is a glycoprotein (GP) IIb/IIIa receptor antagonist, used for the treatment of acute coronary syndrome with high-risk features or ongoing ischemia. Several case reports have described thrombocytopenia as a rare side effect of eptifibatide administration. The exact mechanism remains unclear but may be due to immune destruction of circulating platelets in the peripheral blood. We present the case of acute-onset severe thrombocytopenia in a 76-year-old female undergoing percutaneous coronary intervention.

摘要

依替巴肽是一种糖蛋白（GP）IIb/IIIa受体拮抗剂，用于治疗具有高危特征或持续缺血的急性冠状动脉综合征。几例病例报告描述了血小板减少症是依替巴肽给药的一种罕见副作用。确切机制尚不清楚，但可能是由于外周血中循环血小板的免疫破坏所致。我们报告了一例76岁接受经皮冠状动脉介入治疗的女性急性严重血小板减少症病例。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ee8/8043518/3304eca2b333/ZJCH_A_1871802_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ee8/8043518/3304eca2b333/ZJCH_A_1871802_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ee8/8043518/3304eca2b333/ZJCH_A_1871802_F0001_OC.jpg

相似文献

1
A rare case of eptifibatide-induced thrombocytopenia.依替巴肽诱发血小板减少症的罕见病例。
J Community Hosp Intern Med Perspect. 2021 Mar 23;11(2):269-272. doi: 10.1080/20009666.2021.1871802.
2
Acute Severe Thrombocytopenia Occurring After Administration of Eptifibatide Postpones Emergent Coronary Artery Surgery.依替巴肽给药后发生的急性严重血小板减少症会推迟急诊冠状动脉手术。
Anesth Pain Med. 2016 Jun 21;6(4):e37575. doi: 10.5812/aapm.37575. eCollection 2016 Aug.
3
Eptifibatide-Induced Profound Thrombocytopenia After Percutaneous Intervention for Acute Coronary Syndrome: A Challenging Clinical Scenario.急性冠状动脉综合征经皮介入治疗后依替巴肽诱发的严重血小板减少症：一个具有挑战性的临床病例
Methodist Debakey Cardiovasc J. 2017 Oct-Dec;13(4):248-252. doi: 10.14797/mdcj-13-4-248.
4
Clinical pharmacology of eptifibatide.依替巴肽的临床药理学
Am J Cardiol. 1997 Aug 18;80(4A):11B-20B. doi: 10.1016/s0002-9149(97)00572-9.
5
Intracoronary eptifibatide bolus administration during percutaneous coronary revascularization for acute coronary syndromes with evaluation of platelet glycoprotein IIb/IIIa receptor occupancy and platelet function: the Intracoronary Eptifibatide (ICE) Trial.经皮冠状动脉血运重建术治疗急性冠状动脉综合征时冠状动脉内应用依替巴肽：评估血小板糖蛋白 IIb/IIIa 受体占有率和血小板功能的研究（ICE 试验）。
Circulation. 2010 Feb 16;121(6):784-91. doi: 10.1161/CIRCULATIONAHA.109.882746. Epub 2010 Feb 1.
6
Profound thrombocytopenia after primary exposure to eptifibatide.初次接触依替巴肽后出现严重血小板减少症。
Drug Healthc Patient Saf. 2010;2:163-7. doi: 10.2147/DHPS.S13239. Epub 2010 Sep 21.
7
Safety of glycoprotein IIb-IIIa inhibitors: A heart surgeon's perspective.糖蛋白IIb-IIIa抑制剂的安全性：一位心脏外科医生的观点。
Am Heart J. 1999 Oct;138(4 Pt 2):307-16. doi: 10.1053/hj.1999.v138.a100460.
8
Acute Stent Thrombosis Associated with Eptifibatide-Induced Profound Thrombocytopenia.与依替巴肽诱导的严重血小板减少相关的急性支架内血栓形成
Case Rep Cardiol. 2020 Jun 9;2020:8386709. doi: 10.1155/2020/8386709. eCollection 2020.
9
Acute Profound Thrombocytopenia Induced by Eptifibatide Causing Diffuse Alveolar Hemorrhage.依替巴肽诱发的急性严重血小板减少症导致弥漫性肺泡出血。
Case Rep Crit Care. 2021 Jul 15;2021:8817067. doi: 10.1155/2021/8817067. eCollection 2021.
10
Eptifibatide-induced thrombocytopenia and thrombosis.依替巴肽诱导的血小板减少症和血栓形成。
J Thromb Thrombolysis. 2006 Oct;22(2):151-4. doi: 10.1007/s11239-006-8785-1.

引用本文的文献

1
A woman with eptifibatide (integrilin)-induced thrombocytopenia following treatment of a clot in her coronary artery: A case report and literature review.一名女性在冠状动脉血栓治疗后发生依替巴肽（Integrilin）诱导的血小板减少症：病例报告及文献综述
Clin Case Rep. 2024 Mar 28;12(4):e8694. doi: 10.1002/ccr3.8694. eCollection 2024 Apr.
2
Eptifibatide, an Older Therapeutic Peptide with New Indications: From Clinical Pharmacology to Everyday Clinical Practice.依替巴肽，一种具有新适应证的老治疗性肽：从临床药理学到日常临床实践。
Int J Mol Sci. 2023 Mar 13;24(6):5446. doi: 10.3390/ijms24065446.

本文引用的文献

1
Thrombocytopenia in Critically Ill Patients: Clinical and Laboratorial Behavior and Its Correlation with Short-term Outcome during Hospitalization.危重症患者的血小板减少症：临床与实验室表现及其与住院期间短期预后的相关性
Indian J Crit Care Med. 2017 Dec;21(12):861-864. doi: 10.4103/ijccm.IJCCM_279_17.
2
Heparin-induced thrombocytopenia.肝素诱导的血小板减少症。
Blood. 2017 May 25;129(21):2864-2872. doi: 10.1182/blood-2016-11-709873. Epub 2017 Apr 17.
3
Profound thrombocytopenia induced by clopidogrel with a prior history of long-term safe administration.
氯吡格雷诱导的严重血小板减少症，既往有长期安全用药史。
World J Cardiol. 2010 Jun 26;2(6):160-2. doi: 10.4330/wjc.v2.i6.160.
4
Megakaryocyte impairment by eptifibatide-induced antibodies causes prolonged thrombocytopenia.依替巴肽诱导的抗体导致巨核细胞损伤，引起血小板减少症持续时间延长。
Blood. 2009 Aug 6;114(6):1250-3. doi: 10.1182/blood-2009-02-203034. Epub 2009 May 8.
5
Ticlopidine- and clopidogrel-associated thrombotic thrombocytopenic purpura (TTP): review of clinical, laboratory, epidemiological, and pharmacovigilance findings (1989-2008).噻氯匹定和氯吡格雷相关的血栓性血小板减少性紫癜（TTP）：临床、实验室、流行病学及药物警戒研究结果综述（1989 - 2008年）
Kidney Int Suppl. 2009 Feb(112):S20-4. doi: 10.1038/ki.2008.613.
6
Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa.使用替罗非班或依替巴肽治疗后出现的急性血小板减少症与针对配体占据的糖蛋白IIb/IIIa的特异性抗体有关。
Blood. 2002 Sep 15;100(6):2071-6.
7
Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation.关于弥散性血管内凝血的定义、临床及实验室标准和评分系统
Thromb Haemost. 2001 Nov;86(5):1327-30.
8
Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes.依替巴肽抑制急性冠脉综合征患者血小板糖蛋白IIb/IIIa的作用
N Engl J Med. 1998 Aug 13;339(7):436-43. doi: 10.1056/NEJM199808133390704.
9
Clinical pharmacology of eptifibatide.依替巴肽的临床药理学
Am J Cardiol. 1997 Aug 18;80(4A):11B-20B. doi: 10.1016/s0002-9149(97)00572-9.